obesity

News

Boehringer preps phase 3 for dual-action obesity drug

Armed with results from a phase 2 trial, Boehringer Ingelheim has said it will take its obesity drug candidate survodutide into a phase 3 programme later this year.

News

Four digital weight-loss programmes get NICE support

People seeking help from the NHS to lose weight may soon be eligible to use digital programmes delivered via a smartphone or computer.

News

Novo Nordisk buys Inversago for $1bn as Wegovy sales soar

Sales of its obesity therapies may be accelerating, but Novo Nordisk is showing no signs of pushing the brake pedal on investments in the category.

News

Advantage Novo Nordisk in battle of weight-loss drugs

Novo Nordisk has claimed an edge in the increasingly competitive obesity therapy category after reporting that its Wegovy therapy reduced cardiovascular outcomes by 20% in

Market Access

Weighing the pros and cons, and dollars and cents, of the ne...

Obesity rates in the United States have tripled since the 1980s. According to the CDC, a mind-boggling 41.9% of adults were obese as of 2020.

News

Lilly bulks up in obesity with $1.93bn Versanis buy

Already developing a trio of incretin drugs for obesity, Eli Lilly has its sights set on a candidate with a different mechanism of action that it hopes to acquire via a $1

Boehringer preps phase 3 for dual-action obesity drug

Four digital weight-loss programmes get NICE support

Novo Nordisk buys Inversago for $1bn as Wegovy sales soar

Advantage Novo Nordisk in battle of weight-loss drugs

Weighing the pros and cons, and dollars and cents, of the ne...

Lilly bulks up in obesity with $1.93bn Versanis buy

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

obesity

Editor's Picks